Latest Updates
-
Mamitha Baiju Scores Hat-Trick With ₹200-Crore Hits In A Year: 5 Times Premalu Star Served Effortless Fashion -
Waking Up Multiple Times to Urinate? Doctor Explains When Nighttime Bathroom Trips Need Medical Attention -
Could Your Daily Soft Drink Be Affecting Your Liver? What Doctors Want Regular Consumers To Know -
Vaastu Tips For Children’s Bedroom: From Study Table Placement To Sleep Direction, Expert Shares Simple Rules -
Aja Ekadashi 2026: 6th Or 7th September? Know The Correct Date, Vrat Katha, Tithi And Rituals -
PCOS Is Getting Younger: Why More Teenagers Are Being Diagnosed Than Ever Before -
National Nutrition Week 2026: What To Eat To How To Eat — Expert Shares 7 Ayurveda Rules For Mindful Nutrition -
Kareena Kapoor's Power Dressing At ‘Daayra’ Trailer Launch: 6 Bollywood Actresses Who Owned The Blazer Trend -
Dahi Handi 2026: Why Govindas Form Human Pyramids And What The Tradition Really Means -
Teachers Day 2026: 7 Things Students Can Teach Their Teachers In Return
Half Of Cancer Drugs Approved In UK Show No Survival Benefits
Cancer drugs in UK shown to have no survival benefits whatsoever. Read to find out!
Over half of cancer drugs approved for use in the UK in recent years are not proven to extend life, according to a study. Even where drugs did show survival gains over existing treatments, these were often marginal, the results published in the British Medical Journal (BMJ) show.
Many of the drugs were approved on the basis of indirect ('surrogate') measures that do not always reliably predict whether a patient will live longer or feel better, raising serious questions about the current standards of drug regulation, researchers said.

"When expensive drugs that lack clinically meaningful benefits are approved and paid for within publicly funded healthcare systems, individual patients can be harmed, important societal resources wasted, and the delivery of equitable and affordable care undermined," they said.
The research team based at King's College London and the London School of Economics in the UK analysed reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013. Of 68 cancer indications approved during this period, 57 per cent (39) came onto the market on the basis of a surrogate endpoint and without evidence that they extended survival or improved the quality of patients' lives, researchers said.
After a median of five years on the market, only an additional eight drug indications had shown survival or quality of life gains, they said. Out of 68 cancer indications approved by the EMA, and with a median five years follow-up, only 35 (51 per cent) had shown a survival or quality of life gain over existing treatments or placebo. For the remaining 33 (49 per cent), uncertainty remains over whether the drugs extend survival or improve quality of life.

The findings raise the possibility that regulatory evidence standards "are failing to incentivise drug development that best meets the needs of patients, clinicians, and healthcare systems."
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications